Ibrance

Save as Favorite
Sign in to receive recommendations (Learn more)

Ibrance (chemical name: palbociclib) has been granted accelerated approval by the U.S. Food and Drug Administration to be used in combination with the hormonal therapy Femara (chemical name: letrozole) to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy before in postmenopausal women.

Ibrance also is approved to be used in combination with the hormonal therapy Faslodex (chemical name: fulvestrant) to treat advanced-stage or metastatic, hormone-receptor-positive, HER2-negative breast cancer that has grown after being treated with hormonal therapy in postmenopausal women.

In this section you can learn more about:



Mini 300x125 eoy appeal v2
Back to Top